drugset / Trial / NCT03862716
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising IDegLira, metformin, and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.
Timeline
- Start
- 2019-04-23
- Primary completion
- 2022-06-15
- Completion
- 2023-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IDegLira | Unknown | — | Subcutaneous |
| Subject | Metformin | Small molecule | 2000 mg | Oral |
| Subject | insulin degludec | Protein / enzyme biologic | — | Subcutaneous |